Investor Relations

Timely Disclosure Information
November 05, 2024 StemRIM Announces Patent Registration in Japan for the HMGB1 Peptide, Redasemtide 
October 31, 2024 Presentation Material for Business Plan and Growth Potential 
September 25, 2024 Notice Regarding Appointment of Director Candidates 
September 25, 2024 StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers, Employees, and External Collaborators 
September 11, 2024 Notice Regarding Differences between Non-consolidated Result s for Fiscal Year Ended July 31, 2024 and those for Previous Fiscal Year